Atherosclerotic renal vascular disease (RVD) is a cause of renal failure especially in the elderly. There has never been a clinical trial to determine how effective invasive therapy is over medical therapy to prevent end stage renal disease. The objective of this study was to determine how effective invasive therapy for RVD to prevent renal failure should be from the perspective of the patient to warrant implementation. Subjects included 28 elderly dialysis patients and 26 renal health care workers (HCW). Subjects were asked directly how effective invasive therapy should be if they were to undertake the procedure. Invasive therapy would have to eliminate the need for dialysis permanently by 41 6% for the dialysis patients and 21 4% for the HCW to be acceptable. This difference in efficacy between the two groups was statistically significant (P = 0.014). Efficacy was also determined using a medical decision analysis model that incorporated patient health related quality of life status for dialysis and non-dialysis. To be cost-effective (<$50,000 incremental cost/quality adjusted life year) invasive therapy had to reduce the development of end stage renal failure by 35 1% (M SE) for dialysis patients and 15 1% for HCW.
Introduction
Renal vascular disease is a common cause of end stage renal disease (ESRD) in elderly patients in North American centers [1] . As many as 40% of patients over the age of 65 on dialysis may have ischemic nephropathy. Moreover, patients with ESRD from ischemic nephropathy tend to have extremely high morbidity and mortality rates [1, 2] , There are a number of case series and reports which demonstrate the benefits of invasive therapy (renal artery bypass surgery or angioplasty) to restore renal function in patients with ischemic nephropathy [3] [4] [5] [6] . Therefore many observers have called for a more intensive search and treatment of renal vascular disease to prevent the costs and consequences of ESRD.
Unfortunately renal vascular disease is prevalent in the elderly. However, most patients with renal vascular disease probably die from cardiac and cerebral vascular disease before developing ESRD [1] . Invasive therapy is not always successful (perioperative mortality and progression if not acceleration to ESRD may occur) and is expensive. Furthermore, there has not been a completed randomized controlled trial to determine how effective surgery is over medical therapy.
Decisions about treatment involve three groups of people; patients, physicians (the patient advocate) and third party payers. Physicians want to maximize the benefits to patients and payers want value for service (cost effective care). Neither may necessarily represent the wishes of the patient. Recently clinical epidemiologists have called for more patient-centered input to determine how effective therapeutic procedures should be to warrant implementation [7] . Since there has never been a proper clinical trial completed on renal vascular disease (only one prospective trial in progress), it is not clear, even if the results are positive, whether an improvement in outcome will be clinically relevant from a patient perspective [8] .
The purpose of this report was to determine from the perspective of the patient how effective invasive therapy to correct renal vascular disease must be to prevent ESRD. The required efficacy from the patient's perspective was determined by direct inquiry. An indirect approach, employing a traditional medical decision analysis model that incorporates a patient's probability of death and developing terminal renal failure and their quality of life on and off dialysis, was also examined. This allowed calculation of the smallest efficacy necessary to make invasive therapy superior to medical therapy based purely on outcomes (produce more quality adjusted life years, QALYs) and calculation of cost-effectiveness (how much additional cost for additional QALYs). The former calculates the efficacy that reflects the perspective of the patient advocate (more QALYs) and latter calculates the efficacy that reflects the perspective of the health economist (to implement a therapy as long as the cost per additional QALY is not excessive). These perspectives were then compared to the perspective of the patient. The sample population studied included patients established on dialysis with known or potential renal vascular disease and health care providers of these patients. Renal health care providers were examined since these individuals are most familiar with the treatment of ESRD and are responsible for recommending invasive therapy to patients with RVD.
Methods
Population: Information on 248 stable adult patients from our center on dialysis (peritoneal and hemodialysis) were reviewed. Patients with known renal vascular disease who were relatively well and gave consent were interviewed. In addition, elderly (>60 years) hemodialysis patients with renal failure of unknown etiology that had a history of vascular disease (stroke, ischemic heart disease and/or peripheral vascular disease) were also questioned. Patients sick or unable to communicate were not interviewed. All patients approached agreed to participate, all responses were included. Renal nurses [16] , medical house staff on the nephrology service [5] , and nephrologists [5] were also interviewed.
Interview: Subjects were asked to rate their present quality of health using a rating scale [9] . This method measures preference for a health state by calculating a score from 0 (death) to 1.0 (perfect health), often referred to as a utility. These utilities are more convenient for use in medical decision analysis than multidimensional quality of life instruments. Subjects not on dialysis were also asked to rate their life assuming they were to develop ESRD and start dialysis tomorrow. Those on dialysis were asked to rate their quality of life 5 years ago (or 5 years prior to the start of dialysis or knowledge of renal failure).
Subjects were then asked to consider undergoing an operation on their renal arteries to improve blood flow and kidney function to prevent imminent renal failure (or allow permanent discontinuation of dialysis). The subjects were told that there was some risk of immediate death from the procedure (1% for health care workers and 1-5% for elderly dialysis patients). Graphic charts were used as visual aids. The patients were first asked to consider the procedure if there was a guarantee that it was 100% successful (efficacy 100%, excluding patient death). If they agreed to have the procedure, the efficacy was gradually reduced until they no longer would undergo the procedure. The first refusal was noted as the minimal required efficacy rate for the patient. No other health state or morbidity from the treatment was explicitly stated. This same approach was repeated but patients were told that renal failure was not for another 5 years, that the chance of ever developing ESRD was only 50% but that they had to undergo surgery today or not at all to prevent ESRD. This allowed for a minimal efficacy rate to be calculated if the probability of ever developing ESRD was uncertain (e.g. death before ESRD by an unrelated event). All interviews were carried out by the author and required about 15 minutes. These interviews were repeated in 24 subjects 6 months later.
Model: A Markov model (Figure 1 ) was developed to compare a conservative medical approach (treat hypertension and other risk factors for vascular disease and treat ESRD expectantly) to an invasive approach (perform angiography and if correctable lesion found perform surgery/angioplasty to preserve renal function; if no correctable lesion proceed with medical therapy). A similar model has been previously published [10, 11] . By incorporating reasonable patient mortality rates on and off dialysis, procedure mortality rates, probability rates of developing ESRD and the
